Calidi Biotherapeutics, Inc.
CLDI- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.
Other share classesCLDWW
Q2 2025 vs. Q1 2025
How the institutions holding Calidi Biotherapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 36 | 35 | −1 |
| Shares | 5.46M | 2.86M | −2.60M (−47.7%) |
| Value | $3.09M | $655.8K | −$2.44M (−78.8%) |
New holders (5)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 71,196 | $16.4K | 0.00% |
| HRT Financial LP | 43,609 | $10.0K | 0.00% |
| Raymond James Financial Inc | 31,100 | $7.15K | 0.00% |
| Goldman Sachs Group Inc | 13,205 | $3.04K | 0.00% |
| JPMorgan Chase & Co | 63 | $14 | 0.00% |
Sold out (6)
Institutions that held Calidi Biotherapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| RS Crum Inc. | 55,313 | $31.3K |
| Susquehanna International Group, LLP | 32,642 | $18.5K |
| Two Sigma Securities, LLC | 20,259 | $11.5K |
| XTX Topco Ltd | 16,034 | $9.08K |
| Apollo Management Holdings, L.P. | 12,500 | $7.08K |
| GWM Advisors LLC | 11,000 | $6.23K |